SSE Posts In-Line Operational Performance, Backs Guidance
By Anthony O. Goriainoff
SSE said that its first-quarter operational performance was in line with expectations, and that it is on track to meet its growth targets.
The FTSE 100 energy company said Thursday that its renewable electricity output rose to 2,596 gigawatt-hours in the first quarter of fiscal 2025 from 1,625 GWh the year before. The company said this reflected a return to more normalized weather conditions over the period as well as capacity increases.
Thermal power generation slipped to 3,338 GWh from 3,714 GWh a year earlier. Gas generation fell to 3,072 GWh from 3,218 GWh in the U.K., with gas-fired generation in Ireland falling to 266 GWh from 496 GWh the year prior.
SSE reiterated its target of 175 to 200 pence ($2.28 to $2.60) adjusted earnings per share for fiscal 2027.
The company said its outlook was supported by the U.K. government's enhanced clean-power target, which recognizes a need to invest in renewables, flexible power and electricity networks.
"We remain on track to meet our 2027 growth targets that are underpinned by world-class assets and balance sheet strength, with two-thirds of revenue either regulated or already backed by existing government policy," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
July 18, 2024 02:40 ET (06:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks